Homeostatic expansion as a barrier to lymphocyte depletion strategies

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 357-362

  Zwang, Nicholas A ^a   Turka, Laurence A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoimmunity; Homeostatic proliferation; Lymphodepletion; Transplantation

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 7; THYMOCYTE ANTIBODY; CYTOKINE;

AUTOIMMUNITY; CELL EXPANSION; DRUG MECHANISM; HOMEOSTASIS; HOMEOSTATIC PROLIFERATION; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSTOPERATIVE COMPLICATION; REVIEW; ANIMAL; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CYTOKINES; GRAFT REJECTION; HOMEOSTASIS; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOCYTES;

EID: 84904161997     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000096     Document Type: Review

References (66)

1. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92.
2. Moxham VF, Karegli J, Phillips RE, et al. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 2008; 180:3910-3918.
3. Iida S, Suzuki T, Tanabe K, et al. Transient lymphopenia breaks costimulatory blockade-based peripheral tolerance and initiates cardiac allograft rejection. American J Transplant 2013; 13:2268-2279.
4. Tchao NK, Turka LA. Lymphodepletion and homeostatic proliferation: implications for transplantation. Am J Transplant 2012; 12:1079-1090.
5. Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H mediated depletion for CD4 and CD8 T cells in peripheral blood. Transplant Int 2006; 19:927-936.
6. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465-474.
7. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008; 8:338-347.
8. van der Windt DJ, Smetanka C, Macedo C, et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010; 10:773-783.
9. Marco MRL, Dons EM, van der Windt DJ, et al. Posttransplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumabmediated depletion in heart-transplanted cynomolgus monkeys. Transplant Immunol 2013; 29:88-98.
10. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93:813-821.
11. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+Foxp3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8:792-802.
12. Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37:129-138.
13. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naïve human CD4+Foxp3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-2990.
14. Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4+ T cells is associated with T-cell activation and not the induction of FOXP3+ T regulatory cells. Blood 2009; 114:5003-5006.
15. Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. PNAS 2013; 110:20200-20205.
16. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10:2132-2141.
17. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function monitoring in renal transplantation after thymoglobin induction therapy. Human Immunol 2009; 70:882-890.
18. Lu Y, Suzuki J, Guillioli M, et al. Induction of self-antigen-specific Foxp3+ regulatory T cells in the periphery by lymphodepletion treatment with antimouse thymocyte globulin in mice. Immunology 2001; 134:50-59.
19. Bouvy AP, Kho MML, Klepper M, et al. Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in kidney transplant patients. Transplantation 2013; 96:904-913.
20. Den Braber I, Mugwagwa T, Vrisekoop N, et al. Maintenance of peripheral naïve T cells is sustained by thymus output in mice but not humans. Immunity 2012; 36:288-297.
21. Sauce D, Larsen M, Fastenackels S, et al. Lymphopenia-driven homeostatic regulation of naïve T cells in elderly and thymectomized young adults. J Immunol 2012; 189:5541-5548.
22. Kimura M, Pobezinsky LA, Guinter TI, et al. IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death. Nat Immunol 2013; 14:143-152.
23. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305.
24. Schluns KS, Williams K, Ma A, et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827-4831.
25. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195:1541-1548.
26. Goldrath AW, Sivakumar PV, Glaccum M, et al. Cytokine requirements for acute and basal homeostatic proliferation of naïve and memory CD8+ T cells. J Exp Med 2002; 195:1515-1522.
27. Stoklasek TA, Colpitts SL, Smilowitz HM, Lefrançois L. MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL15R( complex. J Immunol 2010; 185:6857-6865.
28. Purton JF, Tan JT, Rubinstein MP, et al. Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med 2007; 204:951-961.
29. Huntington ND, Alves NL, Legrand N, et al. IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci USA 2011; 108:6217-6222.
30. Van Belle TL, Dooms H, Boonefaes T, et al. IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25high CD4+ T cells. PLOS ONE 2012; 7:e45299.
31. Lucas PJ, Kim SJ, Mackall CL, et al. Dysregulation of IL-15 mediated T-cell homeostasis in TGF-beta dominant negative receptor transgenic mice. Blood 2006; 108:2789-2795.
32. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009; 31:131-144.
33. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T-cell dependent and -independent mechanisms. Immunity 2006; 25:455-471.
34. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006; 25:441-454.
35. Zhang N, Bevan MJ, et al. TGF-( signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nature Immunol 2012; 13:667-674.
36. Johnson LDS, Jameson SC. TGF-( sensitivity restrains CD8+ T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15. PLoS ONE 2012; 7:e42268.
37. Espino-Paisan L, de la Calle H, Fernández-Arguero M, et al. A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes. Immunogenetics 2011; 63:255-258.
38. Festen EA, Goyette P, Green T, et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet 2011; 7:e1001283.
39. Wiede F, La Gruta NL, Tiganis T. PTPN2 attenuates T-cell lymphopeniainduced proliferation. Nat Commun V 2014; 5:3073.
40. Li QJ, Chau J, Ebert PJ, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129:147-161.
41. Frison H, Giono G, Thébault P, et al. Hoxb4 overexpression in CD4 memory phenotype T cells increases the central memory population upon homeostatic proliferation. PLOS ONE 2013; 8:e81573.
42. Abraham C, Griffith J, Miller J. The dependence for leukocyte functionassociated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand. J Immunol 1999; 162:4399-4405.
43. Kandula S, Abraham C. LFA-1 on CD4+ T cells is required for optimal antigen-dependent activation in vivo. J Immunol 2004; 173:4443-4451.
44. Uzel G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology 2001; 121:958-964.
45. Sarin R, Abraham C. CD18 is required for optimal lymphopenia-induced proliferation of mouse T cells. Am J Physiol Gastrointest Liver Physiol 2012; 303:G851-G860.
46. Chu YW, Memon SA, Sharrow SO, et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004; 104:1110-1119.
47. Rosenberg SA, Sportès C, Ahmazadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-319.
48. Sportès C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naïve T cell subsets. J Exp Med 2008; 205:1701-1714.
49. Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogenic stem cell transplantation. Blood 2012; 120:4882-4891.
50. Hennion-Tscheltzoff O, Leboeuf D, Gauthier SD, et al. TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy. Blood 2013; 121:4684-4693.
51. Swainson L, Kinet S, Mongellaz C, et al. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 2007; 109:1034-1042.
52. Azevedo RI, Soares MV, Barata JT, et al. IL-7 sustains CD31 expression in human naïve CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood 2009; 113:2999-3007.
53. Yamada Y, Boskovic S, Aoyama A, et al. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant 2012; 12:330-340.
54. Lee S, Yamada Y, Tonsho M, et al. Alefacept promotes immunosuppressionfree renal allograft survival in nonhuman primates via depletion of recipient memory T cells. Am J Transplant 2013; 13:3223-3229.
55. Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.
56. Weaver TA, Charafedding AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15:746-749.
57. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stemcell transplantation. Biol Blood MarrowTransplant2012;18:1835- 1844.
58. Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224-3230.
59. Ross D, Jones M, Komanduri K, Levy RB. Antigen and lymphopenia-driven donor T cells are differentially diminished by posttransplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19:1403-1438.
60. Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistant to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5:211ra157.
61. Stouvenel L, Auffray C, Martin B, et al. IL-2 and IL-7 determine the homeostatic balance between the regulatory and conventional CD4+cell compartments during peripheral T cell reconstitution. J Immunol 2012; 189:3339-3346.
62. Saadoun D, Rosenzwaig M, Joly F, et al. Regulatory T-cell responses to lowdose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067-2077.
63. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graftversus-host disease. N Engl J Med 2011; 365:2055-2066.
64. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5:179ra43.
65. Brown IE, Blank C, Kline J, et al. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006; 177:4521-4529.
66. Kaiser AD, Gadiot J, Guislain A, Blank CU. Mimicking homeostatic proliferation in vitro generates T cells with high antitumor function in nonlymphopenic hosts. Cancer Immunol Immunother 2013; 62:503-515.